TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04605159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of placebo (lyophilized sucrose reconstituted with NaCl solution) administered intramuscularly in the non-dominant arm at Day 1.
Study: NCT04365153
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL of 5% dextrose infused IV over 2 hours
Study: NCT01158274
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00393393
Drug: intra-articular injection of Hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00475358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03311724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04167553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.~In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total.
Study: NCT02819323
Drug: PEG-ELS
Approvals — FDA: no, EMA: no, PMDA: no
Description: polyethylene glycol based bowel preparation
Study: NCT02819323
Drug: BLI800
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI800 bowel preparation
Study: NCT01118273
Drug: Naproxen Sodium 440 mg (BAYH6689)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
Study: NCT01118273
Drug: Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
Study: NCT01118273
Drug: Naproxen Sodium 220 mg (BAYH6689)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
Study: NCT01118273
Drug: DPH 50mg
Normalized name: phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
Study: NCT01118273
Drug: Ibuprofen 400 mg / Diphenhydramine citrate 76 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
Study: NCT00327379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of placebo (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
Study: NCT01989312
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04384562
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo pill is administered only once.
Study: NCT00229970
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single injection
Study: NCT03340909
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
Study: NCT02108171
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
Study: NCT00822900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours.
Study: NCT04230330
Drug: IV L-asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6000 Units/m2 on Days 2 to 8 every 21 days
Study: NCT03611608
Drug: LY3316531
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03611608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02057458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill designed to mimic the sildenafil treatment
Study: NCT03331861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar dosing regime as active comparator
Study: NCT03781739
Drug: MANP
Normalized name: Multimineral/Multivitamin Oral Tablet [MANPOWER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters
Study: NCT00573599
Drug: Imitrex SubQ, saline IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imitrex SubQ, saline IV
Study: NCT04605861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Placebo Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
Study: NCT00143663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks
Study: NCT00004873
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01921751
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 PO twice daily, 5 days/week, beginning on the first day of radiation therapy and ending on the last day of radiation therapy.
Study: NCT01785459
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Intravenous injection of Prochlorperazine
Study: NCT01075412
Drug: [F18]Fluorothymidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLT PET scan 5 mCi (+/- 10%)
Study: NCT00552175
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo taken orally every day
Study: NCT01496131
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m\^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).
Study: NCT00000580
Drug: immunoglobulins, intravenous
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04018339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing an inert placebo
Study: NCT02153528
Drug: double rimfampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained
Study: NCT03548675
Drug: TCA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).
Study: NCT02153528
Drug: Standard TB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Study: NCT02431936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill made to look identical to Prazosin intervention.
Study: NCT01833611
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo qd
Study: NCT01784770
Drug: Azithromycin IV
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.
Study: NCT01425827
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: similar looking tablets to the active agent for 16 weeks
Study: NCT00658762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, oral, BID, 8 weeks, with 2 week taper
Study: NCT01229618
Drug: Hyperpolarized Pyruvate (13C) injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
Study: NCT01286090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet taken orally 4 times a day for up to 8 weeks.
Study: NCT00770718
Drug: Recombinant Activated Factor VII (rFVIIa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is \>1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given.
Study: NCT04489745
Drug: Androgen deprivation therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03225456
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-nasal placebo
Study: NCT04239833
Drug: Placebo SH-1028 tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of Placebo SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT00018733
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01298752
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
Study: NCT03459807
Drug: Anti-Hypertensive medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of standard Anti-Hypertensive medications
Study: NCT00449592
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Zincol 1 Tab TID from day -6/-7 until discharge
Study: NCT00449592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo 1 Tab TID from day -6/-7 until discharge
Study: NCT00359281
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
Study: NCT00448903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 0,9%
Study: NCT01746485
Drug: UT-15C
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01891500
Drug: Inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
Study: NCT01664559
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac 30mg intramuscular injection, 1cc volume
Study: NCT01664559
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection
Study: NCT00220415
Drug: SPM 927
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03655535
Drug: BTI320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-systemic galactomannan complex polysaccharide
Study: NCT03211403
Drug: SHR4640
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 or placebo once daily for a week
Study: NCT01448902
Drug: OC000459
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC000459 200mg bid for 8 days
Study: NCT01448902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bid for 8 days
Study: NCT01734265
Drug: Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01734265
Drug: Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02534688
Drug: LNG-IUS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00617500
Drug: Hormones
Normalized name: Other hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 1 mg and a drospirenone 2mg/day (3 months)
Study: NCT04021589
Drug: Weileshu
Approvals — FDA: no, EMA: no, PMDA: no
Description: a probiotics products which help to rebuild homeostasis of gut microbiome
Study: NCT00950989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 single SC injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
Study: NCT00950989
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.
Study: NCT00803686
Drug: Oral rsCT tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
Study: NCT00803686
Drug: Oral Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
Study: NCT04021589
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT00803686
Drug: Oral rsCT tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.
Study: NCT00803686
Drug: Fortical (rsCT) nasal spray
Normalized name: Fortical Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
Study: NCT01916408
Drug: Wobenzym plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
Study: NCT01916408
Drug: PL 1
Normalized name: ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
Study: NCT00091104
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04688775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously
Study: NCT03041025
Drug: GSK2330811
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.
Study: NCT03041025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9 percent weight per volume sodium chloride).
Study: NCT01897844
Drug: ITF2984 (100, 2000, 3000 mcg bid)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01897844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00813592
Drug: SOM230B
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOM230 is an injectable somatostatin analogue. Like natural somatostatin and other somatostatin analogues (SRIFa), SOM230 exerts its pharmacological activity via binding to somatostatin receptors (sst). There are five known somatostatin receptors: sst 1, 2, 3, 4 and 5. Somatostatin receptors are expressed in different tissues under normal physiological conditions. Somatostatin analogues activate these receptors with different potencies (Schmid and Schoeffter 2004) and this activation results in a reduced cellular activity and inhibition of hormone secretion. Somatostatin receptors are strongly expressed in many solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted e.g. acromegaly (Freda 2002), GEP/NET tumors (Oberg, et al 2004) and Cushing's disease.
Study: NCT01225731
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC administration of Placebo
Study: NCT01759277
Drug: Control: Femoral perineural local anesthetic infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive a femoral nerve block and postoperative ropivacaine 0.2% infusion
Study: NCT01759277
Drug: Experimental: Adductor Canal perineural local anesthetic infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive an adductor canal nerve block and postoperative ropivacaine 0.2% infusion
Study: NCT02236247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo pill (identical to ivabradine) will be administered twice daily
Study: NCT01113424
Drug: Nicorette® (Nicotine Gum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of marketed nicotine gum 2 mg or 4 mg
Study: NCT01252745
Drug: 10.0 mg of Testosterone, 4.0% TID
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01252745
Drug: 13.5 mg of Testosterone, 4.5% B.I.D
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01252745
Drug: 11.25 mg of Testosterone, 4.5% T.I.D
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03261310
Drug: Acetaminophen or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively.
Study: NCT01659580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225mg bid
Study: NCT01840579
Drug: G-CSF (pegfilgrastim) 3.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a subcutaneous injection on Day 4 of Cycle 1
Study: NCT04315194
Drug: clarithromycin-naproxen-oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir treatment alone for hospitalised paediatric influenza patients.
Study: NCT01435941
Drug: Non-steroidal anti-inflammatory drug (NSAID)
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class
Study: NCT01435941
Drug: Triptan
Normalized name: Oxitriptan
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
Study: NCT02329080
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen
Study: NCT02695901
Drug: Nanoparticle solution of M. alternifolia oil (0.3%).
Approvals — FDA: no, EMA: no, PMDA: no
Description: At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
Study: NCT02034201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00725881
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.
Study: NCT00239278
Drug: prednisolone, 30 mg once daily and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04742283
Drug: DE-126 Ophthalmic Solution 0.002% QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: DE-126 Ophthalmic Solution QD evening and Vehicle QD Morning
Study: NCT02424097
Drug: 1,100pm F-toothpaste and 0.5%NaF rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care at-home:~Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)